Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
NEW YORK, Nov. 25, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) securities between February 10, 2014 and November 9, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/alexion-pharmaceuticals. There is no cost or obligation to you.
According to the complaint, during the Class Period, Alexion made false and/or misleading statements and/or failed to disclose: (1) that the Company employed improper sales practices with respect to its product Soliris; (2) that the Company’s revenues from Soliris sales were unlikely to be sustainable; and (3) that as a result of the above, Alexion’s public statements were materially false and misleading at all relevant times.
On November 4, 2016, Alexion cancelled an appearance at the Credit Suisse Healthcare Conference. The Company also failed to file its Quarterly Report on Form 10-Q with the SEC within two days of its earnings announcement on October 27, 2016. On November 9, 2016, Alexion announced that the Company would not be able to timely file its financial and operating results for the quarter ended September 30, 2016. When this news was announced, shares of Alexion fell in value, causing investors harm.
If you suffered a loss in Alexion you have until January 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/alexion-pharmaceuticals.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
